Healthcare [ 12/13 ] | Drug Manufacturers - General [ 64/164 ]
NASDAQ | Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0.00 | -0.23 Increased by +100.00% |
| Nov 13, 23 | -0.26 | -0.08 Decreased by -225.00% |
| Aug 30, 23 | -0.10 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.59 M Decreased by -98.15% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.27 M Increased by +47.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -1.34 M Increased by +9.08% | Decreased by N/A% - |
| Dec 31, 22 | 0.00 - | -1.35 M - | Decreased by N/A% - |
| Sep 30, 22 | 0.00 - | -1.81 M - | Decreased by N/A% - |
| Jun 30, 22 | 0.00 - | -2.42 M - | Decreased by N/A% - |
| Mar 31, 22 | N/A - | -1.48 M - | - - |